Janssen Research & Development LLC, of Raritan, N.J., a unit of Johnson & Johnson, reported phase III results showing that the use of initial combination therapy of canagliflozin and metformin extended release (XR) in people with type 2 diabetes with higher A1C levels and who treat their type 2 diabetes with diet and exercise only – where monotherapy is unlikely to be adequate to reach glycemic goals – was effective and generally well tolerated.